INOVIO PHARMACEUTICALS, INC. Goodwill and Intangible Asset Impairment
INOVIO PHARMACEUTICALS, INC. (INO) reported Goodwill and Intangible Asset Impairment of $12.50 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GoodwillAndIntangibleAssetImpairment · last filed 2024-03-06
- INOVIO PHARMACEUTICALS, INC. goodwill and intangible asset impairment for the quarter ending 2023-12-31 was $0.00.
- INOVIO PHARMACEUTICALS, INC. goodwill and intangible asset impairment for fiscal 2023 was $12.50M.
| Period end | Goodwill and Intangible Asset Impairment 3 month | Goodwill and Intangible Asset Impairment 9 month | Goodwill and Intangible Asset Impairment 12 month |
|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $12.50M 10-K · filed 2024-03-06 | |
| 2023-09-30 | $12.50M 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |